{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Athira Pharma, Inc.
Is Athira Pharma, Inc. technically bullish or bearish?
As of June 9, 2025, the technical trend has shifted to mildly bearish, influenced by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST.
Who are in the management team of Athira Pharma, Inc.?
As of March 2022, the management team of Athira Pharma, Inc. includes Ms. Kelly Romano, who serves as a Director.
What does Athira Pharma, Inc. do?
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and combat neurodegeneration. It has a market cap of $12.57 million and reported a net profit loss of $9 million as of March 2025.
How big is Athira Pharma, Inc.?
As of Jun 18, Athira Pharma, Inc. has a market capitalization of 12.57 million, with net sales of 0.00 million and a net profit of -79.74 million over the latest four quarters. Shareholder's funds are 44.84 million and total assets are 58.78 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
